Weight ManagementAlso known as: ALT-801, GLP-1/glucagon dual agonist
Pemvidutide
GLP-1/glucagon dual receptor agonist from Altimmune in Phase 2b for obesity and MASH (metabolic-associated steatohepatitis). Shows ~15% weight loss with significant liver fat reduction.
Half-Life
~6-7 days
Dose Range
1.2-2.4 mg/week
Frequency
1× weekly
Vial Sizes
2.4 mg
Mechanism of Action
Balanced GLP-1 and glucagon receptor co-agonist. GLP-1 component reduces appetite; glucagon component increases hepatic fatty acid oxidation and energy expenditure, making it particularly effective for liver fat reduction (MASH/NAFLD).
Source: PMID: 37578887 (MOMENTUM Phase 2)
Dosing Protocol
| Typical Dose | 1.2-2.4 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~6-7 days |
| Common Vial Sizes | 2.4 mg |
Reconstitution Example
Vial
2.4 mg
Water
1 mL
Concentration
2.4 mg/mL
Per Unit (100u syringe)
24 mcg
Dose of 1200 mcg = 50 units on a 100-unit insulin syringe
Dosing Quick Reference
Pemvidutide— Dosing Guide
Dose Range
1.2-2.4 mg/week
Half-Life
~6-7 days
Frequency
1× weekly
Route
Subcutaneous
2.4 mg vial
💧 1 mL BAC water|📐 2.4 mg/mL concentration|💉 24 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code